Table 1. Basic clinical characteristics of all participants.
| Characteristics | AML group | Control group |
|---|---|---|
| Age/years, median (range) | 47.5 (14–86) | 38.5 (24–72) |
| Age group/n (%) | ||
| ≥60 years | 30 (23.4) | 6 (37.5) |
| <60 years | 98 (76.6) | 10 (62.5) |
| Gender/n (%) | ||
| Men | 73 (57.8) | 9 (56,2) |
| Women | 55 (42.2) | 7 (43.8) |
| FAB subtypes/n (%) | ||
| M0 | 4 (3.1) | |
| M1 | 6 (4.7) | |
| M2 | 68 (53.1) | |
| M4 | 15 (11.7) | |
| M5 | 33 (25.8) | |
| M6 | 1 (0.8) | |
| M7 | 1(0.8) | |
| Prognosis Risk/n (%) | ||
| Good | 20 (15.7) | |
| Intermediate | 59(46) | |
| Poor | 49 (38.3) | |
| Cytogenetics/n (%) | ||
| Normal | 63 (49.2) | |
| Complex | 10 (7.8) | |
| inv(16) or t(16;16)/CBFβ/MYH11 | 5 (3.9) | |
| t(8;21)/AML1/ETO | 21 (16.4) | |
| 11q23/MLL | 8 (6.2) | |
| t(9;22)/BCR/ABL1 | 3 (2.4) | |
| Others | 18 (14.1) | |
| Molecular genetics/n (%) | ||
| FLT3-ITD | 23 (17.9) | |
| c-Kit | 14 (10.9) | |
| NPM-1 | 20 (15.6) | |
| TP53 | 2 (1.5) | |
| RUNX1 | 3 (2.3) | |
| ASXL1 | 7 (5.5) | |
| DNMT3a | 7 (5.5) | |
| SF3B1 | 1 (0.8) | |
| CEBPA double mutation | 7 (5.5) | |
| IDH1 | 8 (6.3) | |
| IDH2 | 8 (6.3) |